 
|
ISTA Pharmaceuticals Ranked Number
Twelve in Deloitte's Technology Fast 500 Program for Fastest
Growing Companies in North AmericaIRVINE, CA - November 13, 2008 — ISTA Pharmaceuticals Inc. has been named number twelve in Deloitte's prestigious Technology Fast 500 Program for North America, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America by Deloitte LLP, one of the nation’s leading professional services organizations. Rankings are based on the percentage revenue growth over the five years from 2003–2007. ISTA’s growth in revenues has been driven by the introduction of a number of new ophthalmic therapeutic products, particularly Xibrom® (bromfenac ophthalmic solution) 0.09%. Introduced to the market in 2005, Xibrom 0.09% is ISTA’s twice-daily topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery. "We are very pleased to be ranked number twelve in Deloitte’s Technology Fast 500 program for North America," said Vicente Anido Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "Since its U.S. launch, Xibrom 0.09% has attained 32% dollar market share in its category with ophthalmologists and continues to show significant growth. During the first half of this year, sales of ISTA’s products in total have increased 40% over the same period in 2007, and we are now the fifth largest prescription ophthalmic company in the United States. We look forward to additional growth and further expansion of our presence in the ophthalmic community." In addition to ranking number twelve in North America, ISTA's increase in revenues of 21,075% from 2003 to 2007 resulted in a number one ranking in the Technology Fast 50 for Orange County, California. The average increase in revenues among companies who made the Technology Fast 50 for this region was 1630%. "Deloitte’s Technology Fast 500 recognizes companies who have achieved extraordinary growth in North America’s most innovative and competitive market sectors," said Phil Asmundson, Deloitte LLP vice chairman and national managing partner for Technology, Media and Telecommunications. "We congratulate ISTA Pharmaceuticals on this significant accomplishment." To qualify for the Technology Fast 500, companies must have had operating revenues of at least $50,000 in 2003 and $5,000,000 in 2007, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify. Companies from the regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte’s Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com. About Xibrom® (bromfenac ophthalmic solution) 0.09% Xibrom is a topical non-steroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery. Xibrom, approved in 2005, is the first and only FDA-approved twice-daily NSAID for inflammation and reduction of pain following cataract surgery. Xibrom was the fastest-growing ophthalmic product in 2007, according to IMS data. Xibrom, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the product in the U.S. in 2005. About ISTA Pharmaceuticals ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $4.7 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com. About Deloitte As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. # # # Contact Vince Anido, 949-788-5311, vanido@istavision.com, Lauren Silvernail, 949-788-5302, lsilvernail@istavision.com, both of ISTA Pharmaceuticals; Juliane Snowden, jsnowden@burnsmc.com, or Justin Jackson, jjackson@burnsmc.com, 212-213-0006, of Burns McClellan, for ISTA Pharmaceuticals |